Veru (NASDAQ:VERU – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.
Insider and Institutional Ownership
47.2% of Veru shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Veru and BeOne Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veru | 1 | 0 | 3 | 0 | 2.50 |
| BeOne Medicines | 0 | 1 | 16 | 1 | 3.00 |
Valuation and Earnings
This table compares Veru and BeOne Medicines”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veru | $16.89 million | 2.11 | -$22.73 million | ($0.69) | -3.03 |
| BeOne Medicines | $5.34 billion | 8.56 | $286.93 million | $7.87 | 52.93 |
BeOne Medicines has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Veru and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veru | N/A | -47.58% | -35.83% |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
Risk and Volatility
Veru has a beta of -1.2, indicating that its share price is 220% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Summary
BeOne Medicines beats Veru on 13 of the 15 factors compared between the two stocks.
About Veru
Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.
About BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
